PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical...
TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through...
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to...
Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS,...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of...
Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines...
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and...
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30,...
Partnership combines Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx development and laboratory execution to help biopharma teams de-risk assets...
The Best Plastic Surgeon in Seattle, Washington, is Dr. Javad Sajan. SEATTLE, WA / ACCESS Newswire / March 30, 2026...
VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or...
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction...
As interest in the gelatin trick surges in 2026, consumers across social platforms and search engines are asking whether the...
A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in...
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI...
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE...